CLDI · Calidi Biotherapeutics, Inc.
$1.35
+0.03 (+1.89%)
At close · Aug 31
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$3.41M
Shares
2.58M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$45K
FY2022
Net Income
-$19.91M
+10.1%
FY2025
Operating Margin
-51395.56%
FY2022
Diluted EPS
-$95.20
+83.3%
FY2025
Operating Cash Flow
-$21.29M
-8.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | — | — | — | $45K | |
| $9.86M | $9.74M | $8.88M | $13.01M | $7.26M | |
| $7.99M | $10.5M | $12.9M | $15.98M | $15.9M | |
| $1.71M | $1.65M | $1.54M | — | — | |
| $17.85M | $20.24M | $21.78M | $28.99M | $23.17M | |
| -$17.85M | -$20.24M | -$21.78M | -$28.99M | -$23.13M | |
| — | — | — | — | -51395.56% | |
| -$16.14M | -$18.59M | -$20.24M | — | — | |
| $360K | $192K | -$419K | -$208K | -$2.29M | |
| -$17.49M | -$20.05M | -$22.2M | -$29.2M | -$25.42M | |
| $17K | $15K | $14K | $16K | $11K | |
| -$17.4M | -$19.91M | -$22.14M | -$29.22M | -$25.43M | |
| — | — | — | — | -56504.44% | |
| — | -$157K | -$66K | — | — | |
| -$23.46M | -$25.58M | -$23.81M | -$29.22M | $1.07M | |
| -$17.49M | -$19.89M | -$22.12M | -$29.25M | -$25.44M | |
| USD/shares | -$37.91 | -$95.20 | -$571.20 | -$3,327.36 | $5,740.80 |
| USD/shares | -$37.91 | -$95.20 | -$571.20 | -$3,327.36 | $5,740.80 |
| shares | — | 268.875 | 41.6875 | 8781.25 | 4429.6875 |
| shares | — | 268.875 | 41.6875 | 8781.25 | 4429.6875 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.60×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 127 similar-size Biotechnology companies (of 508 listed).
Key facts
CIK
1855485
CUSIP
320703408
13F (30d)
15 filings
15 filers
Visit website
Investor relations